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Geisinger Health System, Danville, PA, USATo return or not to return the results of genomics research: that has
been the question at the crux of an ongoing debate spawned by the
increasingly rapid evolution of genomics.1 Like many debates, this one
arises from conﬂicting perspectives on broader concerns: for example,
the purported distinction between research and patient care, the rela-
tionship between health care institutions and the communities they
serve, and the role of patient- and research-participant-engagement in
such debates (and in their resolution).
In 2012, Geisinger began to lay the groundwork for a signiﬁcant ex-
pansion of theMyCode Community Health Initiative, a research platform
comprised not only of a biobank established ﬁve years earlier but also of
the clinical data collected in the electronic health records of the
biobank's patient–participants and of the investigations made possible
by these resources. Advances in genomic knowledge, coupled with
steady decreases in sequencing costs, supplied the immediate context
for this effort, which also entailed extensive internal discussion and
patient–participant engagement focused on the ethical question, should
Geisinger return clinically actionable results of genomics research to
MyCode's patient–participants whose sequenced genomes yield such
results?
In convening the internal discussions, the aimwas to enlist organiza-
tional leaders, clinicians, and investigators in a process of ethical analy-
sis and reﬂection for the purpose of identifying what obligations, if any,
Geisinger has toward its patient–participants with regard to the return
of results. Through engagement with the patient–participants, nearly
100 of whom were convened through focus groups described below,
the aim was to solicit their views on the very same question.2
After the focus groups, the views of the engaged participants were
clear: they overwhelmingly favored the return of results. Additional dis-
cussions were then held with leadership, researchers and Geisinger's⁎ Corresponding author.
E-mail address: wafaucett@geisinger.edu (W.A. Faucett).
1 The literature emanating from this debate is now quite extensive and has grown sig-
niﬁcantly following the 2013 publication of the ACMG recommendations for reporting of
incidentalﬁndings in clinical exome and genome sequencing. For a representative critique
of the ACMG's recommendations, see Susan MWolf, George J Annas, and Sherman Elias,
“Respecting Patient Autonomy in Clinical Genomics: New Recommendations on
Incidental Findings Go Astray,” Science. 2013 May 31; 340(613b): 1049–1050. For a de-
fense of the recommendations, see Amy L McGuire et al., “Ethics and Genomic Incidental
Findings,” Science. 2013 May 31; 340(6136): 1047–1048.
2 David J Carey et al., “The Geisinger MyCode Community Health Initiative: An
Electronic Health Record-Linked Biobank for Precision Medicine Research,” Genetics in
Medicine. In press. [doi: 10.1038/gim.2015.187].
http://dx.doi.org/10.1016/j.atg.2016.01.003
2212-0661/© 2016 The Authors. Published by Elsevier B.V. This is an open access article underInstitutional Review Board (IRB) and ultimately, Geisinger did indeed
decide to return genomic results to that subset of MyCode participants
whose sequenced genomes are found to contain one or more of the ge-
netic variants on a deﬁned list (based in part on theMarch 2013 clinical
testing recommendations of the American College of Medical Genetics
and Genomics3) and to integrate those clinically actionable results in
genetically informed plans of care for these patient–participants.
Soon after this decision, in early 2014, Geisinger announced an
ambitious collaboration in genomics discovery with the Tarrytown,
NY-based Regeneron Pharmaceuticals and embarked upon the antici-
pated expansion of MyCode—the current goal of which is to increase
the ranks of patient–participants to at least 250,000 over ﬁve years.
Against the backdrop of President Obama's recently announced
Precision Medicine Initiative (PMI), which calls for the development of
a one-million-participant cohort, Geisinger hopes to become a funded
member of the PMI consortium and is considering a many-fold increase
in the size ofMyCode, inspired, in largemeasure, by rapid growth in the
number of consented participants.4
Here we describe the development of the ethical rationale for
returning genomic results to patient–participants in the MyCode
Community Health Initiative with special attention to the aforemen-
tioned internal discussions, reﬂections and focus groups through
which the institution sought to engage patient–participants.
1. “Make my hospital right—Make it the best”
The Geisinger Health System encompasses more than 30,000 em-
ployees, a 1100-member multi-specialty group practice, nine hospital
campuses, two research centers and a 467,000-member health
plan. Now one of the nation's largest rural health care systems,
Geisinger is the outgrowth of the vision of Abigail Geisinger, a widow
who committed her late husband's fortune to the establishment of a
hospital to serve the health care needs of the thriving community of
Danville, Pennsylvania. To the Mayo-trained Harold Foss, M.D., the
surgeon-architect who Abigail entrusted with the realization of her
vision, she issued the mandate that has resonated throughout the sub-
sequent decades with successive generations of Geisinger leaders,3 Robert C. Green et al., “ACMG Recommendations for Reporting of Incidental Findings
in Clinical Exome and Genome Sequencing. 2013; 15(7): 565–574.
4 Francis S. Collins and Harold Varmus, “A New Initiative on Precision Medicine,” New
England Journal of Medicine. 2015; 372(9): 793–795.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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make it the best.
In the 1950s, the pursuit of Abigail's original mandate began to
extend beyond the provision of clinical care to the residents of the
surrounding community to include the conduct of research. In the
mid-2000s, Geisinger's research leaders became keenly interested in
the potential establishment of a biobank as a resource for basic studies
into heart disease, obesity, and other problems of concern to the
surrounding community. Because such a resource would depend upon
biospecimens voluntarily donated by patients, those same leaders
thought it essential to proceed by ﬁrst surveying Geisinger's patients
in order to gauge their understanding of and attitudes toward biomed-
ical research in general and genomics/genetics in particular. At stake
was the trust that had developed between the institution and its
surrounding community over the course of nearly a century. In order to
maintain that trust, it would be important to determine if Geisinger's pa-
tients were inclined to support a venture that would be fundamentally
dependent on their good will. As the results of the survey and of
subsequent focus groups showed, a clearmajority supported the develop-
ment of a biobankwith a focus ongenetics, althoughGeisinger leadership,
researchers, and the patient participants themselves did evince concerns
about the potential for discrimination based on genetic information.
In 2007, Geisinger's biobank, MyCode, was ofﬁcially launched.
Research and institutional leadership predicted that at some point in
the future the cost of sequencing would drop and that the National
Institutes of Health (NIH) or another government agency would fund
the development of a large biobank for population-based sequencing.
With its stable multi-generational population, willing participants and
early adoption of an electronic medical record, Geisinger wanted to
make sure that it was ready for such a government funded project. Con-
sistent with the expressed preferences of the survey and focus group
participants, a broad, general consent was developed for the purposes
of recruiting Geisinger patients and obtaining their biospecimens and
their permission to use the information stored in their electronic health
records, both for broad data sharing and future unspeciﬁed research.5
Although the original consent left the door open to returning results, it
stated results would not be deposited in the electronic health record
due to the concern about potential discrimination. From 2007 to 2013,
Geisinger's practices with regard to returning results reﬂected the
then-dominant view—that is, that results should not be returned.2. The research/clinical care distinction and
the patient/participant perspective
The initial survey and the focus groups, the results of which were
instrumental in the founding of MyCode, were efforts to engage
Geisinger's patients in research and discovery. As such, they reﬂected
the growing awareness of the value of engagement—of patient,
participant, and community engagement—in all phases of the scientiﬁc
process, from the design of investigations to the dissemination of their
ﬁndings.
Moreover, both the initial survey and the focus groups yielded an
understanding of Geisinger that was (and remains) at odds with a
decades-old tradition of bioethics dogma concerning patient care and5 The ethical requirements for consent to biobank-based research have also been a focus
of considerable discussion and debate, although it is arguable that a consensusnowafﬁrms
the ethical validity of a broad consent for this purpose. Questions and concerns about
broad consents for biobank research are explored in B Hofmann, “Broadening
Consent—Diluting Ethics?” Journal of Medical Ethics. 2009 February; 35(2):125–129. For
a defense of broad consent, see Mats G Hansson et al., “Should Donors Be Allowed to Give
Broad Consent to Future Biobank Research? Lancet Oncology. 2006; 7: 266–269. Partici-
pants in a 2013workshop convened by the Department of Bioethics at the Clinical Center,
National Institutes of Health also afﬁrmed the ethical validity of broad consents; for a sum-
mary of that discussion, see Christine Grady et al., “Broad Consent for Research with Bio-
logical Samples: Workshop Conclusions.” American Journal of Bioethics. 2015; 15(9): 34–
42.research, that is, the idea that the two activities are—and must be
kept—ethically and conceptually distinct, even if, in reality, the line be-
tween them is blurred. This idea was originally articulated and
enshrined in the Belmont Report of 1979, which set forth the ethical
principles for regulating human subjects research in the United States.
According to Belmont, caring for patients and conducting research are
ethically distinct because the former is focused on the needs of an indi-
vidual, while the latter is oriented to the advancement of a social or pub-
lic good, i.e., the good of new knowledge in the biomedical sciences.6
Given that alleged distinction, some have argued that researchers
have no obligation to cross the divide and, for example, return clinically
relevant (“actionable”) genomic results to biobank participants. Others
have reached a similar conclusion for different reasons, arguing that
the return of such results could or would be potentially more harmful
than beneﬁcial to the participants in such research.7
For the participants in the initial survey and the focus groups,
however, there was no such divide, no clear distinction, between the
Geisinger that cared for them as patients and the Geisinger that seeks
to use their biospecimens and their clinical data in research, with the ul-
timate aim of improving their care. This dual commitment to improving
care for the local and broader community and, at the same time, giving
excellent care to individualswas (andhas been repeatedly) endorsed by
Geisinger's patient–participants, just as it was embraced as an institu-
tional obligation by the system's leaders, clinicians, and investigators.
In time, that understanding of Geisinger, on the part of MyCode's
ﬁrst patient–participants, and that institutional obligation, on the part
of Geisinger's leaders, clinicians, and investigators, set the stage for an
additional round of ethical reﬂections, spurred by some salient realities
and by some pressing questions. The realities included the fact that the
individuals recruited to participate inMyCodewere (and are) Geisinger
patients: a condition of participation is that one must be a patient
receiving care somewhere within the system. Another fact is that inves-
tigations in genomic discovery made possible by the gift of their
biospecimens routinely yield information of potential beneﬁt to those
same patients. Would withholding that information from patients, in
deference to the dogma about the distinction between research and
patient care or out of concerns almost solely focused on risk, be an
ethically defensible posture for Geisinger to assume? What about the
time- and resource-intensive nature of returning that information
to MyCode's patients-participants? Could that be a legitimate reason
for withholding, rather than disclosing potentially beneﬁcial informa-
tion to these individuals and the clinicians who care for them? And,
what would those same patient–participants say about this question
of whether to withhold or return potentially beneﬁcial genomic
information?
In early 2013, answers to these questions about returning genomic
results were supplied through a series of focus groups with MyCode
participants, conducted under the auspices of the NHGRI-funded
eMERGE consortium, which Geisinger joined in 2011 to spur progress
in the integration of genomic data into electronic health records—and
thus in clinical care. At Geisinger's ﬂagship hospital and at local primary
care clinics, six focus groups were held with a total of ninety-three
MyCode participants. (The participants were 57% female and 43%
male. The age distribution matched the MyCode population with the
majority being over age 50. Nearly half of the participants had been
Geisinger patients for twenty years or more and 85% reported receiving
the majority of their medical care in the Geisinger Health System.) Five
types of genomic research results were discussed, including:
(1) pharmacogenomics; (2) recessive carrier status; (3) increased risk6 National Commission for the Protection of Human Subjects of Biomedical and Behav-
ioral Research, “The Belmont Report: Ethical Principles for the Protection of Human Sub-
jects of Research,” April 18, 1979, bhttp://www.hhs.gov/ohrp/humansubjects/guidance/
belmont.htmlN (2 November 2015).
7 Gail P. Jarvik et al., “Return of Genomic Results to Research Participants: The Floor, the
Ceiling, and the Choices in Between,” The American Journal of Human Genetics. 2014; 94:
818–826.
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(4) increased risk for non-treatable or non-preventable condition
(Alzheimer's); and (5) genetic changes that we currently do not
understand.
A large majority of the participants favored the return of all ﬁve
types of results, with nothing withheld due to concerns about psycho-
logical harm or clinical actionability. A few participants were hesitant
about the value of the results for their own health care but were
convinced that their results could be of value to their children and
grandchildren. They were also interested in learning their results if
they could provide additional information that might increase their
value for research. Altruism—the desire to help others—was the major
motivation cited by participants to explain their willingness to be
recruited for the biobank and to participate in the focus groups. They
also favored returning results to both biobank participants and their
health care providers and recommended that education and medical
support should be provided for patients and providers. And they
wanted clinically actionable results to be placed in theirmedical records
and thereby to be made available to all of their healthcare providers.
As mentioned, the results of this second round of focus groups
generated yet another round of intense discussion and reﬂection
among Geisinger's research and institutional leaders. Some were
hesitant to return results, but in time, a majority coalesced around the
moral conviction that the institution actually has a duty to do so—a
duty to care by making every effort to use clinically actionable genomic
results for the clinical beneﬁt of any patient–participant. With its
original position on returning results (“we may do so but we will not
deposit the results in the electronic health record”), crafted a year
before the passage of the Genetic Information Non-Discrimination Act,Geisinger sought to signal its respect for concerns about privacy and
conﬁdentiality on the part of MyCode's ﬁrst participants. In revising its
original position, Geisinger sought to respect the overwhelming
support—even demand—for returning results on the part of the partici-
pants in the 2013 focus groups, and, at the same time,make good on this
duty to care for these participants as patients, as individuals whose care
might beneﬁt from the return of results.
Thus, in late summer 2013, the decision was made to move forward
and begin to develop a process to return clinically actionable results
from the MyCode Community Health Initiative. The original broad
consent form was modiﬁed to discuss—and seek the participant's
permission to–return of results and the deposition of those results in
the electronic health record. Due to the potential for therapeutic
misconception, a related decision was made to return only clinically
actionable results, a provision that is also explained in the consent
form. In addition, the consent form also assures patient–participants
that they are free to opt out at any point in theprocesswithout incurring
any penalties or any other changes to their rights or healthcare services.
In October 2013, Geisinger's institutional review board approved these
revisions in the MyCode consent. This approval that was the outcome
of two interrelated processes: one of patient–participant engagement
and the other of internal discussion and ethical reﬂection.
Geisinger has just begun the process of returning clinically action-
able results to patient–participants. And in so doing, it has begun to
grapple with the very real practical challenge of returning these results
in away that beneﬁts individual patient–participants and, through both
internally and externally funded studies, answers research questions of
critical importance to the effective integration of genomics in health
care.
